Wedge Capital Management’s Royalty Pharma RPRX Stock Holding History

Wedge Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$42.4M	Sell	726,068 -44,354	-6%	-$2.62M	0.74%	29
2026 Q2	$43.2M	Sell	770,422 -120,418	-14%	-$6.27M	0.71%	28
2026 Q1	$42.7M	Sell	890,840 -149,128	-14%	-$6.53M	0.79%	29
2025 Q4	$40.2M	Sell	1,039,968 -152,473	-13%	-$5.81M	0.72%	30
2025 Q3	$42.1M	Sell	1,192,441 -22,480	-2%	-$814K	0.71%	30
2025 Q2	$43.8M	Buy	1,214,921 +200,122	+20%	+$6.63M	0.78%	28
2025 Q1	$31.6M	Buy	+1,014,799	New	+$32.2M	0.61%	80

Other funds holding RPRX

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Hosking Partners London, United Kingdom $2.81B AUM 67.07% 1-Year Est. Return

Kepler Cheuvreux Nyon $1.65B AUM 36.86% 1-Year Est. Return

Foster Victor Wealth Advisors Greenville, South Carolina $2.02B AUM 20.94% 1-Year Est. Return

Kirr Marbach & Co Columbus, Indiana $530M AUM 14.37% 1-Year Est. Return

Triasima Portfolio Management Montreal, Quebec, Canada $758M AUM 48.16% 1-Year Est. Return

Fideuram - Intesa Sanpaolo Private Banking Turin $3.5B AUM 45.13% 1-Year Est. Return

Sumitomo Mitsui DS Asset Management Tokyo, Japan $14.8B AUM 30.39% 1-Year Est. Return

Wedge Capital Management's RPRX Position: Q3 2026 in Review

Wedge Capital Management reduced its Royalty Pharma (RPRX) stake by 5.8% in Q3 2026, selling an estimated $2.62M and leaving 726,068 shares worth $42.4M. The position accounts for 0.74% of the portfolio, ranked #29.

Wedge Capital Management first reported a position in RPRX in Q1 2025 and has held it in 7 quarters since. The position peaked at $43.8M in Q2 2025. 129 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

Wedge Capital Management held 726,068 shares of Royalty Pharma worth $42.4M as of Q3 2026.
Wedge Capital Management sold 44,354 Royalty Pharma shares in Q3 2026, an estimated $2.62M.
Royalty Pharma made up 0.74% of Wedge Capital Management's portfolio in Q3 2026, its #29 holding.
Wedge Capital Management first reported a position in Royalty Pharma in Q1 2025 and has held it in 7 quarters since.
Wedge Capital Management's Royalty Pharma position peaked at $43.8M in Q2 2025.
129 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Wedge Capital Management's 13F filing for Q3 2026, filed 13 Oct 2026.